These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

244 related items for PubMed ID: 30394916

  • 1. Low Low-Density Lipoprotein Levels Are Associated With, But Do Not Causally Contribute to, Increased Mortality in Sepsis.
    Walley KR, Boyd JH, Kong HJ, Russell JA.
    Crit Care Med; 2019 Mar; 47(3):463-466. PubMed ID: 30394916
    [Abstract] [Full Text] [Related]

  • 2. Proprotein Convertase Subtilisin/Kexin Type 9 Loss-of-Function Is Detrimental to the Juvenile Host With Septic Shock.
    Atreya MR, Whitacre BE, Cvijanovich NZ, Bigham MT, Thomas NJ, Schwarz AJ, Weiss SL, Fitzgerald JC, Allen GL, Lutfi R, Nowak JE, Quasney MW, Shah AS, Wong HR.
    Crit Care Med; 2020 Oct; 48(10):1513-1520. PubMed ID: 32769621
    [Abstract] [Full Text] [Related]

  • 3. Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Brief Overview.
    Noel ZR, Beavers CJ.
    Am J Med; 2017 Feb; 130(2):229.e1-229.e4. PubMed ID: 27751895
    [Abstract] [Full Text] [Related]

  • 4. Association Between Genetically Proxied Inhibition of HMG-CoA Reductase and Epithelial Ovarian Cancer.
    Yarmolinsky J, Bull CJ, Vincent EE, Robinson J, Walther A, Smith GD, Lewis SJ, Relton CL, Martin RM.
    JAMA; 2020 Feb 18; 323(7):646-655. PubMed ID: 32068819
    [Abstract] [Full Text] [Related]

  • 5. Long-term exposure to air pollution raises circulating levels of proprotein convertase subtilisin/kexin type 9 in obese individuals.
    Macchi C, Ferri N, Favero C, Cantone L, Vigna L, Pesatori AC, Lupo MG, Sirtori CR, Corsini A, Bollati V, Ruscica M.
    Eur J Prev Cardiol; 2019 Apr 18; 26(6):578-588. PubMed ID: 30477320
    [Abstract] [Full Text] [Related]

  • 6. AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C Assessment with Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined with Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 trial.
    Desai NR, Kohli P, Giugliano RP, O'Donoghue ML, Somaratne R, Zhou J, Hoffman EB, Huang F, Rogers WJ, Wasserman SM, Scott R, Sabatine MS.
    Circulation; 2013 Aug 27; 128(9):962-9. PubMed ID: 23884353
    [Abstract] [Full Text] [Related]

  • 7. The Central Role of Proprotein Convertase Subtilisin/Kexin Type 9 in Septic Pathogen Lipid Transport and Clearance.
    Walley KR, Francis GA, Opal SM, Stein EA, Russell JA, Boyd JH.
    Am J Respir Crit Care Med; 2015 Dec 01; 192(11):1275-86. PubMed ID: 26252194
    [Abstract] [Full Text] [Related]

  • 8. Effect of Preoperative Administration of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor on Carotid Artery Stenting.
    Shingai Y, Kimura N, Doijiri R, Takahashi K, Yokosawa M, Kanoke A, Kikuchi T, Sugawara T, Tominaga T.
    World Neurosurg; 2020 Mar 01; 135():e36-e42. PubMed ID: 31655235
    [Abstract] [Full Text] [Related]

  • 9. Impact of PCSK9 loss-of-function genotype on 1-year mortality and recurrent infection in sepsis survivors.
    Genga KR, Lo C, Cirstea MS, Leitao Filho FS, Walley KR, Russell JA, Linder A, Francis GA, Boyd JH.
    EBioMedicine; 2018 Dec 01; 38():257-264. PubMed ID: 30473376
    [Abstract] [Full Text] [Related]

  • 10. Role of lipoproteins and proprotein convertase subtilisin/kexin type 9 in endotoxin clearance in sepsis.
    Walley KR.
    Curr Opin Crit Care; 2016 Oct 01; 22(5):464-9. PubMed ID: 27552305
    [Abstract] [Full Text] [Related]

  • 11. Low-Density Lipoprotein Receptor-Dependent and Low-Density Lipoprotein Receptor-Independent Mechanisms of Cyclosporin A-Induced Dyslipidemia.
    Kockx M, Glaros E, Leung B, Ng TW, Berbée JF, Deswaerte V, Nawara D, Quinn C, Rye KA, Jessup W, Rensen PC, Meikle PJ, Kritharides L.
    Arterioscler Thromb Vasc Biol; 2016 Jul 01; 36(7):1338-49. PubMed ID: 27150391
    [Abstract] [Full Text] [Related]

  • 12. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
    Urban D, Pöss J, Böhm M, Laufs U.
    J Am Coll Cardiol; 2013 Oct 15; 62(16):1401-8. PubMed ID: 23973703
    [Abstract] [Full Text] [Related]

  • 13. Apolipoprotein(a) phenotype determines the correlations of lipoprotein(a) and proprotein convertase subtilisin/kexin type 9 levels in patients with potential familial hypercholesterolemia.
    Afanasieva OI, Ezhov MV, Razova OA, Afanasieva MI, Utkina EA, Pokrovsky SN.
    Atherosclerosis; 2018 Oct 15; 277():477-482. PubMed ID: 30270088
    [Abstract] [Full Text] [Related]

  • 14. Circulating proprotein convertase subtilisin-kexin type 9, all-cause mortality, and cardiovascular mortality: The Ludwigshafen Risk and Cardiovascular Health study.
    Silbernagel G, Scharnagl H, Kleber ME, Stojakovic T, März W.
    Eur J Prev Cardiol; 2017 Jul 15; 24(10):1095-1101. PubMed ID: 28436724
    [Abstract] [Full Text] [Related]

  • 15. Discordant response of low-density lipoprotein cholesterol and lipoprotein(a) levels to monoclonal antibodies targeting proprotein convertase subtilisin/kexin type 9.
    Edmiston JB, Brooks N, Tavori H, Minnier J, Duell B, Purnell JQ, Kaufman T, Wojcik C, Voros S, Fazio S, Shapiro MD.
    J Clin Lipidol; 2017 Jul 15; 11(3):667-673. PubMed ID: 28506388
    [Abstract] [Full Text] [Related]

  • 16. HIV and Hepatitis C-Coinfected Patients Have Lower Low-Density Lipoprotein Cholesterol Despite Higher Proprotein Convertase Subtilisin Kexin 9 (PCSK9): An Apparent "PCSK9-Lipid Paradox".
    Kohli P, Ganz P, Ma Y, Scherzer R, Hur S, Weigel B, Grunfeld C, Deeks S, Wasserman S, Scott R, Hsue PY.
    J Am Heart Assoc; 2016 Apr 29; 5(5):. PubMed ID: 27130349
    [Abstract] [Full Text] [Related]

  • 17. Associations of lipids and lipid-modifying drug target genes with atrial fibrillation risk based on genomic data.
    Tao Y, Wang Y, Yin Y, Zhang K, Gong Y, Ying H, Jiang R.
    Lipids Health Dis; 2024 Jun 08; 23(1):175. PubMed ID: 38851763
    [Abstract] [Full Text] [Related]

  • 18. Association of lipid-lowering drug targets with risk of cutaneous melanoma: a mendelian randomization study.
    Miao L, Miao T, Zhang Y, Hao J.
    BMC Cancer; 2024 May 17; 24(1):602. PubMed ID: 38760735
    [Abstract] [Full Text] [Related]

  • 19. Assessing the Impact of PCSK9 and HMGCR Inhibition on Liver Function: Drug-Target Mendelian Randomization Analyses in Four Ancestries.
    Rosoff DB, Bell AS, Wagner J, Mavromatis LA, Hamandi A, Park L, Jung J, Lohoff FW.
    Cell Mol Gastroenterol Hepatol; 2024 May 17; 17(1):29-40. PubMed ID: 37703945
    [Abstract] [Full Text] [Related]

  • 20. The effects of single- and multiple-dose administration of bococizumab (RN316/PF-04950615), a humanized IgG2Δa monoclonal antibody binding proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects treated with and without atorvastatin: Results from four phase I studies.
    Gumbiner B, Joh T, Liang H, Wan H, Levisetti M, Vana AM, Shelton DL, Forgues P, Billotte S, Pons J, Baum CM, Garzone PD.
    Cardiovasc Ther; 2018 Feb 17; 36(1):. PubMed ID: 29078037
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.